Sandostatin lar and Dyslipidaemia - a phase IV clinical study of FDA data

Summary:

Dyslipidaemia is reported as a side effect among people who take Sandostatin lar (octreotide acetate), especially for people who are female, 60+ old, have been taking the drug for 2 - 5 years also take Dostinex, and have Diarrhea.

The phase IV clinical study analyzes which people have Dyslipidaemia when taking Sandostatin lar. It is created by eHealthMe based on reports of 38,376 people who have side effects when taking Sandostatin lar from the FDA, and is updated regularly.

What is Sandostatin lar?

Sandostatin lar has active ingredients of octreotide acetate. It is often used in acromegaly. eHealthMe is studying from 38,437 Sandostatin lar users. Check the latest studies of Sandostatin lar.

What is Dyslipidaemia?

Dyslipidaemia (abnormal amount of lipids) is found to be associated with 836 drugs and 711 conditions by eHealthMe. Check the latest studies of Dyslipidaemia.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

38,376 people reported to have side effects when taking Sandostatin lar.
Among them, 18 people (0.05%) have Dyslipidaemia.

Could Sandostatin lar cause Dyslipidaemia?

Among these 18 people:

How long have people been on Sandostatin lar when they have Dyslipidaemia? *

What is the gender of people who have Dyslipidaemia when taking Sandostatin lar? *

female: 72.22 %
male: 27.78 %

What is the age of people who have Dyslipidaemia when taking Sandostatin lar? *

What are other drugs people take besides Sandostatin lar? *

What are other side effects people have besides Dyslipidaemia? *

High Blood Pressure: 8 people, 44.44%
High Blood Cholesterol: 7 people, 38.89%
Insulin-Like Growth Factor Increased: 6 people, 33.33%
Headache (pain in head): 6 people, 33.33%
Gallstones (stone formation by bile component): 6 people, 33.33%
Osteoporosis (bones weak and more likely to break): 6 people, 33.33%
Blood Growth Hormone Increased: 5 people, 27.78%
Weakness: 5 people, 27.78%
Anaemia (lack of blood): 5 people, 27.78%
Urinary Tract Infection: 5 people, 27.78%

What are the existing conditions these people have? *

Short-Bowel Syndrome (a condition in which the body cannot absorb enough fluids and nutrients because part of the small intestine is missing): 2 people, 11.11%
Oedema (fluid collection in tissue): 2 people, 11.11%
Neuroendocrine Carcinoma Metastatic (cancer tumour that arise from cells of the endocrine (hormonal) and nervous systems and spreads to other part): 2 people, 11.11%
High Blood Pressure: 2 people, 11.11%
Diarrhea: 2 people, 11.11%
Pituitary Tumor: 1 person, 5.56%
Pain: 1 person, 5.56%
Neuroendocrine Tumor: 1 person, 5.56%
Nausea (feeling of having an urge to vomit): 1 person, 5.56%
Metastatic Carcinoid Tumor: 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Sandostatin lar and have Dyslipidaemia?

- Check whether Dyslipidaemia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Sandostatin lar:

Sandostatin lar (38,437 reports)

Dyslipidaemia treatments and more:

Dyslipidaemia (42,009 reports)

Browse all side effects of Sandostatin lar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Dyslipidaemia:

Dyslipidaemia (836 drugs)

Browse all the conditions that are associated with Dyslipidaemia:

Dyslipidaemia (711 conditions)

Related publications that referenced our studies

Saif MW, "Rheumatoid arthritis associated with the use of Sandostatin? LAR? depot in a patient with pancreatic neuroendocrine tumor", An association or a coincidence? The first case report, 2017 Jan .
Azkur D, Yoldas T, Toyran M, Kocabas CN, "A pediatric case of anaphylaxis due to octreotide", Asian Pacific journal of allergy and immunology, 2011 Dec .
Saif MW, "Rheumatoid arthritis associated with the use of Sandostatin? LAR? depot in a patient with pancreatic neuroendocrine tumor", An association or a coincidence? The first case report, 2017 Jan .
Azkur D, Yoldas T, Toyran M, Kocabas CN, "A pediatric case of anaphylaxis due to octreotide", Asian Pacific journal of allergy and immunology, 2011 Dec .

How the study uses the data?

The study uses data from the FDA. It is based on octreotide acetate (the active ingredients of Sandostatin lar) and Sandostatin lar (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.